[Exclusive] Celltrion Holdings takes first steps for U.S. listing

2024. 1. 15. 20:06
글자크기 설정 파란원을 좌우로 움직이시면 글자크기가 변경 됩니다.

이 글자크기로 변경됩니다.

(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.

[Celltrion]
Celltrion Holdings is planning to list on Nasdaq as early as the end of 2024, a move that will allow the South Korean company to accurately evaluate its value in the global capital market and continue to grow as a healthcare investment company.

According to Maeil Business Newspaper on January 15th, 2024, Celltrion Group Chairman Seo Jung-jin attended the Federation of Korean Industries’ Future Leaders Camp that took place in Gangneung, Gangwon Province as the event’s first speaker the day before, where he announced the upcoming Nasdaq listing.

“I have asked the relevant departments to list Celltrion Holdings on Nasdaq as early as the end of the year, or by early 2025 at the latest,” Seo said, adding, “Celltrion Holdings will be the first relatively large Korean company to list on Nasdaq.” He continued, “We plan to use 5 trillion won ($3.72 billion) of the funds from the Nasdaq listing as seed money for the ‘Global Healthcare Fund’,” adding, “We plan to attract a large number of overseas investors to Korea and set up a 100 trillion won fund” and “I will do everything in my power to help young people have a smoother experience in getting their startups off the ground than I did.”

Celltrion Group reorganized its affiliates to make its governance more transparent at the end of 2023. The first step of this integration, whereby the group merged with Celltrion Healthcare, was the listing of new shares on January 12th, 2024, and the process will be completed once the integrated Celltrion entity merges with Celltrion Pharm, Inc. within the next six months.

Seo plans to list the holding company, which was formed during this reorganization process, within the year and develop it into an investment company. Industry sources believe that Nasdaq is the best source to attract external capital as more than half of Celltrion Group sales are generated overseas.

“Companies that generate big sales overseas or are familiar with foreign investors have the advantage of raising more funds via a Nasdaq listing. But U.S. legal and accounting standards are applied when listing on Nasdaq, and the group’s related costs, including concerns about lawsuits, could increase,” according to a financial investment industry official.

A second official said, “A company’s market capitalization must exceed 10 trillion won after listing for major institutions to consider investing in it and for the company to enjoy the benefits of a Nasdaq listing.”

By Kim hee-soo, Shim Hee-jin, Lee Ji Eun

Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지

이 기사에 대해 어떻게 생각하시나요?